We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If approved, asciminib would beef up Novartis' CML portfolio, which is a big earner for the company. Tasigna made sales of $1.8 billion last year, and despite generics Glivec is still a ...

CML Unlocks AI’s Full Potential with Enhanced Pattern Recognition, Prediction, and Real-Time Decision-Making for Defense, Autonomous Systems, and Next-Gen Computing BOULDER, Colo., March 20 ...